Misplaced Pages

5-Chloro-αET

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Pharmaceutical compound
5-Chloro-αET
Clinical data
Other names5-Chloro-AET; 5-Chloro-α-ethyltryptamine; PAL-526; PAL526
Drug classSerotonin releasing agent; Serotonin 5-HT2A receptor agonist
Identifiers
IUPAC name
  • 1-(5-chloro-1H-indol-3-yl)butan-2-amine
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC12H15ClN2
Molar mass222.72 g·mol
3D model (JSmol)
SMILES
  • CCC(CC1=CNC2=C1C=C(C=C2)Cl)N
InChI
  • InChI=1S/C12H15ClN2/c1-2-10(14)5-8-7-15-12-4-3-9(13)6-11(8)12/h3-4,6-7,10,15H,2,5,14H2,1H3
  • Key:LBURKXNSAFJELW-UHFFFAOYSA-N

5-Chloro-αET (code name PAL-526), or 5-chloro-AET, also known as 5-chloro-α-ethyltryptamine, is a serotonergic agent of the tryptamine and α-alkyltryptamine families. It is the derivative of α-ethyltryptamine (αET or AET) with a 5-chloro substitution. Analogues of 5-chloro-αET include 5-fluoro-αET, 5-chloro-αMT, and 5-fluoro-αMT.

The drug is known to act as a potent serotonin releasing agent (SRA) and relatively weak serotonin 5-HT2A receptor near-full agonist. It shows negligible induction of norepinephrine and dopamine release but does act as a very weak dopamine reuptake inhibitor (DRI). 5-Chloro-αET's EC50Tooltip half-maximal effective concentration and IC50Tooltip half-maximal inhibitory concentration values are 33.2 nM for serotonin release, 249 nM (EmaxTooltip maximal efficacy = 87%) for serotonin 5-HT2A receptor agonism (7.5-fold lower than for serotonin release), 1,838 nM for dopamine reuptake inhibition (55-fold lower than for serotonin release), and >10,000 nM for norepinephrine release. The monoamine release assays were performed in rat brain synaptosomes.

References

  1. ^ Blough BE, Landavazo A, Partilla JS, Decker AM, Page KM, Baumann MH, Rothman RB (October 2014). "Alpha-ethyltryptamines as dual dopamine-serotonin releasers". Bioorg Med Chem Lett. 24 (19): 4754–4758. doi:10.1016/j.bmcl.2014.07.062. PMC 4211607. PMID 25193229. The racemic a-alkyl tryptamines 7a, 7b, 7c, 7d, 7e, and 7f were synthesized by nitro olefin formation followed by lithium ammonium hydride reduction (Scheme 2).32 a-Ethylation of the 5-chloro and 5-fluoro substituted tryptamines, to form 7e and 7f respectively, also weakened NE release activity compared to their a-methyl analogs, but 7e flipped to become a weak DA uptake inhibitor. In the a-ethyltryptamine series, the 5-chloro analog (7e) and 5-fluoro analog (7f) both weakened substantially as 5-HT2A agonists compared to their a-methyl- and non-alkylated tryptamine analogs (7b/7c and 4h/4j), with EC50 values of 249 nM and 246 nM, respectively. Table 1 Comparison of the DAT, SERT, and NET-mediated release activity and 5-HT2A receptor activity of substituted tryptamines Value is IC50 for uptake inhibition in nM.


Monoamine releasing agents
DRAsTooltip Dopamine releasing agents
NRAsTooltip Norepinephrine releasing agents
SRAsTooltip Serotonin releasing agents
Others
See also: Receptor/signaling modulatorsMonoamine reuptake inhibitorsAdrenergicsDopaminergicsSerotonergicsMonoamine metabolism modulatorsMonoamine neurotoxins
Serotonin receptor modulators
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Tryptamines
Tryptamines
N-Acetyltryptamines
α-Alkyltryptamines
Triptans
Cyclized tryptamines
Isotryptamines
Related compounds


Stub icon

This psychoactive drug-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: